Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study.

Journal of medical genetics - 1 Mar 2023

Tiller Jane M, Cousens Nicole E, Kaur Rajneesh, Rowley Simone, Ko Yi-An, Mahale Sakshi, Bankier Agnes, Meiser Bettina, Barlow-Stewart Kristine, Burnett Leslie, Jacobs Chris, James Paul, Trainer Alison, Neil Suzanne, Campbell Ian G, Andrews Lesley, Delatycki Martin

Abstract excerpt

BACKGROUND: Ashkenazi Jewish (AJ) people have a higher incidence of BRCA1/2 pathogenic variants (PVs) than unselected populations. Three BRCA-Jewish founder mutations (B-JFMs) comprise >90% of BRCA1/2 PVs in AJ people. Personal/family cancer history-based testing misses ≥50% of people with B-JFM. METHODS: We compared two population-based B-JFM screening programmes in Australia-using (1) an online tool (Sydney)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Australia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to Breast Neoplasms

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Neoplasms

Source

Identifiers

PMID: 36763037
DOI: 10.1136/jmedgenet-2022-108519

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study.PMID 36763037Read ↗

Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paper.Semantic proximity Read ↗

BRCA awareness and testing experience in the UK Jewish population: a qualitative study.Semantic proximity Read ↗

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.Semantic proximity Read ↗

Community attitudes towards a Jewish community BRCA1/2 testing program.Semantic proximity Read ↗

Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population.Semantic proximity Read ↗

Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.Semantic proximity Read ↗

Evaluating the Effectiveness of a Telehealth Cancer Genetics Program: A BRCA Pilot Study.Semantic proximity Read ↗

Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2.Semantic proximity Read ↗

Attitude towards and factors affecting uptake of population‐based BRCA testing in the Ashkenazi Jewish population: a cohort studySemantic proximity Read ↗

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.Semantic proximity Read ↗

A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testingSemantic proximity Read ↗

Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term secondary lifestyle behavioural outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.